We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ANDRX GIVES UP 180-DAY MARKETING RIGHTS TO GENERIC ZYBAN
ANDRX GIVES UP 180-DAY MARKETING RIGHTS TO GENERIC ZYBAN
May 28, 2004
Generic firm Andrx has given up its 180-day exclusive market rights for a 150-mg strength version of GlaxoSmithKline’s (GSK’s) smoking cessation drug Zyban (bupropion HCl), a move that allows other generic firms to start marketing the product.